Skip to main content

Table 1 Association of clinico-pathological characteristics of ER+/HER2- breast cancer patients with levels of ING1 in the stroma

From: Stromal ING1 expression induces a secretory phenotype and correlates with breast cancer patient survival

Characteristics # of cases (%) ER+/Her2-
Low lng1 High lng1 P-value
Age     
   < 53 72 (16.25) 56 16 0.880
   ≥ 53 371 (83.75) 284 87
Menopausal status     
  Pre-menopausal 26 (5.90) 17 9  
  Peri-menopausal 21 (4.70) 18 3 0.231
  Post-menopausal 321 (72.50) 242 79
  n/a (male) 1 (0.20) 1 0
  Unknown 74 (16.70) 62 12
Stage     
  I 188 (42.40) 148 40 0.365
  II 138 (31.20) 105 33
  III 36 (8.20) 24 12
  IV 5 (1.10) 3 2
  Unknown 76 (17.20) 60 16
Tumor grade     
  1 103 (25.40) 88 15 0.001
  2 247 (60.80) 195 52
  3 56 (13.80) 31 25
Tumor size     
   < 2 cm 223 (53.86) 179 44 0.020
   ≥ 2 cm 191 (46.14) 137 54
Lymph node status     
  Negative 278 (72.77) 220 58 0.103
  Positive 104 (27.23) 74 30
Rx Tamoxifen     
  No 161 (37.44) 118 43 0.196
  Yes 269 (62.56) 212 57
  1. The listed clinico-pathological characteristics were analyzed for their correlation with low/high levels of stromal ING1. Stromal ING1 shows a correlation with tumor grade and size in the ER+/ Her2- group of patients in the cohort